{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T13:48:09Z","timestamp":1765547289181,"version":"3.37.3"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T00:00:00Z","timestamp":1720051200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T00:00:00Z","timestamp":1720051200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100014387","name":"ACADIA Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014387","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s12325-024-02926-6","type":"journal-article","created":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T09:02:09Z","timestamp":1720083729000},"page":"3328-3341","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effect of Hepatic Impairment on Trofinetide Exposures Using an In Silico Physiologically Based Pharmacokinetic Model"],"prefix":"10.1007","volume":"41","author":[{"given":"Mona","family":"Darwish","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Obinna N.","family":"Obianom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James M.","family":"Youakim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inger","family":"Darling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viera","family":"Lukacova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather","family":"Bradley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,7,4]]},"reference":[{"key":"2926_CR1","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/13810","volume":"23","author":"RE Amir","year":"1999","unstructured":"Amir RE, Van den Veyver IB, Wan M, Tran CQ, Francke U, Zoghbi HY. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat Genet. 1999;23:185\u20138.","journal-title":"Nat Genet"},{"key":"2926_CR2","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3389\/fncel.2014.00018","volume":"8","author":"G Baj","year":"2014","unstructured":"Baj G, Patrizio A, Montalbano A, Sciancalepore M, Tongiorgi E. Developmental and maintenance defects in Rett syndrome neurons identified by a new mouse staging system in vitro. Front Cell Neurosci. 2014;8:18.","journal-title":"Front Cell Neurosci"},{"key":"2926_CR3","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1093\/cercor\/bhv078","volume":"26","author":"F Bedogni","year":"2016","unstructured":"Bedogni F, Cobolli Gigli C, Pozzi D, et al. Defects during Mecp2 null embryonic cortex development precede the onset of overt neurological symptoms. Cereb Cortex. 2016;26:2517\u201329.","journal-title":"Cereb Cortex"},{"key":"2926_CR4","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1002\/cne.22009","volume":"514","author":"PV Belichenko","year":"2009","unstructured":"Belichenko PV, Wright EE, Belichenko NP, et al. Widespread changes in dendritic and axonal morphology in Mecp2-mutant mouse models of Rett syndrome: evidence for disruption of neuronal networks. J Comp Neurol. 2009;514:240\u201358.","journal-title":"J Comp Neurol"},{"key":"2926_CR5","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1203\/PDR.0b013e3182242461","volume":"70","author":"S Fehr","year":"2011","unstructured":"Fehr S, Bebbington A, Nassar N, et al. Trends in the diagnosis of Rett syndrome in Australia. Pediatr Res. 2011;70:313\u20139.","journal-title":"Pediatr Res"},{"key":"2926_CR6","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/j.1651-2227.1985.tb10993.x","volume":"74","author":"B Hagberg","year":"1985","unstructured":"Hagberg B. Rett\u2019s syndrome: prevalence and impact on progressive severe mental retardation in girls. Acta Paediatr Scand. 1985;74:405\u20138.","journal-title":"Acta Paediatr Scand"},{"issue":"suppl 1","key":"2926_CR7","first-page":"8","volume":"6","author":"H Leonard","year":"1997","unstructured":"Leonard H, Bower C, English D. The prevalence and incidence of Rett syndrome in Australia. Eur Child Adolesc Psychiatry. 1997;6(suppl 1):8\u201310.","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"2926_CR8","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jpeds.2009.07.015","volume":"156","author":"RS Kirby","year":"2010","unstructured":"Kirby RS, Lane JB, Childers J, et al. Longevity in Rett syndrome: analysis of the North American Database. J Pediatr. 2010;156:135\u2013138.e1.","journal-title":"J Pediatr"},{"key":"2926_CR9","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/ajmg.b.32707","volume":"180","author":"JL Neul","year":"2019","unstructured":"Neul JL, Benke TA, Marsh ED, et al. The array of clinical phenotypes of males with mutations in Methyl-CpG binding protein 2. Am J Med Genet B Neuropsychiatr Genet. 2019;180:55\u201367.","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"2926_CR10","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1007\/s10803-017-3034-3","volume":"47","author":"JB Lane","year":"2017","unstructured":"Lane JB, Salter AR, Jones NE, et al. Assessment of caregiver inventory for Rett syndrome. J Autism Dev Disord. 2017;47:1102\u201312.","journal-title":"J Autism Dev Disord"},{"key":"2926_CR11","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.pediatrneurol.2015.06.003","volume":"53","author":"DC Tarquinio","year":"2015","unstructured":"Tarquinio DC, Hou W, Neul JL, et al. The changing face of survival in Rett syndrome and MECP2-related disorders. Pediatr Neurol. 2015;53:402\u201311.","journal-title":"Pediatr Neurol"},{"key":"2926_CR12","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1073\/pnas.0812394106","volume":"106","author":"D Tropea","year":"2009","unstructured":"Tropea D, Giacometti E, Wilson NR, et al. Partial reversal of Rett Syndrome-like symptoms in MeCP2 mutant mice. Proc Natl Acad Sci U S A. 2009;106:2029\u201334.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2926_CR13","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.ab.2003.08.032","volume":"323","author":"DC Batchelor","year":"2003","unstructured":"Batchelor DC, Lin H, Wen JY, et al. Pharmacokinetics of glycine\u2013proline\u2013glutamate, the N-terminal tripeptide of insulin-like growth factor-1, in rats. Anal Biochem. 2003;323:156\u201363.","journal-title":"Anal Biochem"},{"key":"2926_CR14","doi-asserted-by":"publisher","first-page":"S98","DOI":"10.1016\/j.ejps.2017.05.032","volume":"109","author":"SP Oosterholt","year":"2017","unstructured":"Oosterholt SP, Horrigan J, Jones N, Glass L, Della Pasqua O. Population pharmacokinetics of NNZ-2566 in healthy subjects. Eur J Pharm Sci. 2017;109:S98\u2013107.","journal-title":"Eur J Pharm Sci"},{"key":"2926_CR15","doi-asserted-by":"publisher","first-page":"e1912","DOI":"10.1212\/WNL.0000000000007316","volume":"92","author":"DG Glaze","year":"2019","unstructured":"Glaze DG, Neul JL, Kaufmann WE, et al. Double-blind, randomized, placebo-controlled study of trofinetide in pediatric Rett syndrome. Neurology. 2019;92:e1912\u20131925.","journal-title":"Neurology"},{"key":"2926_CR16","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1038\/s41591-023-02398-1","volume":"29","author":"JL Neul","year":"2023","unstructured":"Neul JL, Percy AK, Benke TA, et al. Trofinetide for the treatment of Rett syndrome: a randomized phase 3 study. Nat Med. 2023;29:1468\u201375.","journal-title":"Nat Med"},{"key":"2926_CR17","doi-asserted-by":"publisher","DOI":"10.1098\/rsob.170216","volume":"8","author":"SM Kyle","year":"2018","unstructured":"Kyle SM, Vashi N, Justice MJ. Rett syndrome: a neurological disorder with metabolic components. Open Biol. 2018;8: 170216.","journal-title":"Open Biol"},{"key":"2926_CR18","unstructured":"Committee for Medicinal Products for Human Use (CHMP). Guideline on the evaluation of the pharmacokinetics of medicinal products in patients with impaired hepatic function. CPMP\/EWP\/2339\/02. 2005. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-evaluation-pharmacokinetics-medicinal-products-patients-impaired-hepatic-function_en.pdf. Accessed 20 Sep 2022."},{"key":"2926_CR19","unstructured":"Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Pharmacokinetics in patients with impaired hepatic function: study design, data analysis, and impact on dosing and labeling. Guidance for industry 2003. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/pharmacokinetics-patients-impaired-hepatic-function-study-design-data-analysis-and-impact-dosing-and. Accessed 20 Sep 2022."},{"key":"2926_CR20","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s40261-022-01156-4","volume":"42","author":"M Darwish","year":"2022","unstructured":"Darwish M, Youakim JM, Harlick J, DeKarske D, Stankovic S. A phase 1, open-label study to evaluate the effects of food and evening dosing on the pharmacokinetics of oral trofinetide in healthy adult subjects. Clin Drug Investig. 2022;42:513\u201324.","journal-title":"Clin Drug Investig"},{"key":"2926_CR21","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s40261-023-01322-2","volume":"44","author":"M Darwish","year":"2024","unstructured":"Darwish M, Nunez R, Youakim JM, Robertson P Jr. Characterization of the pharmacokinetics and mass balance of a single oral dose of trofinetide in healthy male subjects. Clin Drug Investig. 2024;44:21\u201333.","journal-title":"Clin Drug Investig"},{"key":"2926_CR22","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.clinthera.2023.12.007","volume":"46","author":"M Darwish","year":"2024","unstructured":"Darwish M, Youakim JM, Darling I, Lukacova V, Owen JS, Bradley H. A physiologically based pharmacokinetic modeling approach to assess the potential for drug interactions between trofinetide and CYP3A4-metabolized drugs. Clin Ther. 2024;46:194\u2013200.","journal-title":"Clin Ther"},{"key":"2926_CR23","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1002\/bjs.1800600817","volume":"60","author":"RN Pugh","year":"1973","unstructured":"Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60:646\u20139.","journal-title":"Br J Surg"},{"key":"2926_CR24","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1002\/(SICI)1520-6017(200001)89:1<16::AID-JPS3>3.0.CO;2-E","volume":"89","author":"P Poulin","year":"2000","unstructured":"Poulin P, Theil F-P. A priori prediction of tissue:plasma partition coefficients of drugs to facilitate the use of physiologically-based pharmacokinetic models in drug discovery. J Pharm Sci. 2000;89:16\u201335.","journal-title":"J Pharm Sci"},{"key":"2926_CR25","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1097\/MOG.0000000000000176","volume":"31","author":"IH Kim","year":"2015","unstructured":"Kim IH, Kisseleva T, Brenner DA. Aging and liver disease. Curr Opin Gastroenterol. 2015;31:184\u201391.","journal-title":"Curr Opin Gastroenterol"},{"key":"2926_CR26","doi-asserted-by":"publisher","first-page":"189","DOI":"10.2165\/11318160-000000000-00000","volume":"49","author":"TN Johnson","year":"2010","unstructured":"Johnson TN, Boussery K, Rowland-Yeo K, Tucker GT, Rostami-Hodjegan A. A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance. Clin Pharmacokinet. 2010;49:189\u2013206.","journal-title":"Clin Pharmacokinet"},{"issue":"suppl 1","key":"2926_CR27","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/j.1365-2125.2001.00770.x","volume":"52","author":"AS Gross","year":"2001","unstructured":"Gross AS. Best practice in therapeutic drug monitoring. Br J Clin Pharmacol. 2001;52(suppl 1):5\u20139.","journal-title":"Br J Clin Pharmacol"},{"key":"2926_CR28","doi-asserted-by":"publisher","first-page":"5552","DOI":"10.3748\/wjg.v13.i42.5552","volume":"13","author":"AP Betrosian","year":"2007","unstructured":"Betrosian AP, Agarwal B, Douzinas EE. Acute renal dysfunction in liver diseases. World J Gastroenterol. 2007;13:5552\u20139.","journal-title":"World J Gastroenterol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02926-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-024-02926-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02926-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T19:13:28Z","timestamp":1721675608000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-024-02926-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,4]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["2926"],"URL":"https:\/\/doi.org\/10.1007\/s12325-024-02926-6","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"type":"print","value":"0741-238X"},{"type":"electronic","value":"1865-8652"}],"subject":[],"published":{"date-parts":[[2024,7,4]]},"assertion":[{"value":"12 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Mona Darwish, James M. Youakim, and Heather Bradley are employees and hold stock of Acadia Pharmaceuticals Inc. Obinna N. Obianom, Inger Darling, and Viera Lukacova are employees and hold stock of Simulations Plus, Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The clinical studies that were used to validate the PBPK model were conducted in accordance with the ethical standards of the local Institutional Review Boards for each site and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. Informed consent was obtained by the parent or legal guardian on behalf of the study participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}